Azenta Expands Genewiz Business With Licensing Deal, Acquisition
MT Newswires Live10-30 21:20
Azenta (AZTA) said Friday it is expanding its Genewiz genomics business by entering into an exclusive license agreement with Elegen Corp. and by acquiring synthetic biology company SynPlexity.
The Elegen agreement adds cell-free DNA manufacturing technology aimed at improving DNA quality, production speed and scalability, the company said.
The SynPlexity acquisition adds technology that enables researchers to produce thousands of gene variants in a single library, including AI-generated designs, Azenta said.
Financial terms of the license agreement and the acquisition were not disclosed.
Azenta shares were 3.1% lower in premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
